Abstract
Genetic Engineering & Biotechnology NewsVol. 39, No. 5 OpinionEthical and Biosafety Oversight of New CAR T-Cell ProductsDevelopment of synthetic immunology challenges us to protect study participants and the publicDaniel Kavanagh, PhDDaniel Kavanagh, PhDDaniel Kavanagh, PhD, is senior scientific advisor, gene therapy at WCG (WIRB-Copernicus Group). Previously, he was on the faculty at Harvard Medical School, where he conducted gene therapy research and was vice chair of an Institutional Biosafety Committee overseeing human gene transfer studies.Search for more papers by this authorPublished Online:27 Apr 2019https://doi.org/10.1089/gen.39.05.05AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 39Issue 5May 2019 InformationCopyright © GEN PublishingTo cite this article:Daniel Kavanagh, PhD.Ethical and Biosafety Oversight of New CAR T-Cell Products.Genetic Engineering & Biotechnology News.May 2019.12-13.http://doi.org/10.1089/gen.39.05.05Published in Volume: 39 Issue 5: April 27, 2019PDF download
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
